Results for tag: "Metastatic Bone Disease Drug"

Metastatic Bone Disease (MBD) is a type of cancer that affects the bones and is caused by the spread of cancer cells from other parts of the body. Treatment for MBD typically involves a combination of chemotherapy, radiation therapy, and targeted therapies. Oncology drugs are used to treat MBD and can be divided into two categories: systemic therapies and local therapies. Systemic therapies are drugs that are taken orally or intravenously and are designed to target cancer cells throughout the body. Local therapies are drugs that are injected directly into the affected area and are designed to target cancer cells in the bone. The Metastatic Bone Disease Drug market is a rapidly growing segment of the oncology drug market. It is driven by the increasing prevalence of MBD, the development of new treatments, and the increasing demand for personalized treatments. Companies in the market include Novartis, Amgen, Merck, Pfizer, and Bristol-Myers Squibb. Show Less Read more